Liquid biopsy may guide HER2-targeted therapy rechallenge in metastatic disease

▸ TREATMENT

Real-world data suggest that monitoring HER2 amplification through liquid biopsy can help identify patients with HER2-amplified metastatic colorectal cancer who may benefit from rechallenge with anti-HER2 therapy. (JCO Precision Oncology)